Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (brand names Ozempic and Wegovy) and tirzepatide (brand name Mounjaro), are medications used to treat type 2 diabetes and obesity.
October 10, 2025
high
temporal
Baseline description of the drug class and common brand examples.
Use of GLP-1 receptor agonists can produce atypical tracer uptake on PET and CT scans that may mimic disease and therefore has the potential to lead to additional diagnostic tests, incorrect cancer assessments, or delays in treatment.
October 10, 2025
high
temporal
Clinical implication of altered imaging patterns associated with metabolic-effecting medications.